Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue reading
Hemex Team Press Release
HEMEX opens subsidiary in Belgium, expanding its presence in the EU
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
At HEMEX we are committed to our community and are constantly looking for ways to give back. We are especially mindful of educational programs with a long-term positive impact.
At HEMEX, we regularly organize invitation-only pitch days, where selected startups get the opportunity to pitch in front of potential investors. The focus of our last 2019 pitch session was on startups seeking to revolutionize cancer diagnosis and treatment. Thank you Christina Vallgren, Marcus Palm, Martin Stauber, Seline Eisenring, Michael Krauthammer and Peter Nestorov for […]
On 14th November 2019, our CEO Pascal Winnen signed a cooperation agreement with the Luoyang Science and Innovation Park in Henan, China’s most populated province. Under the Agreement, HEMEX will support the property developer Forton Group with attracting innovative Swiss startups for its newly built 133’000 m2 life science park. In exchange, HEMEX and its […]
The European Commission has awarded a consortium led by AMT Medical including HEMEX with a 2.2 MEUR grant under its “Fast-Track to Innovation (FTI)” program. Under the proposal HEMEX will plan, coordinate and execute a multicentric, pan-European study in order to obtain CE-mark for the Excimer Laser Assisted Non-occlusive Anastomosis (ELANA) Heart Bypass System in Patients […]
Funding
Scailyte raises CHF 2.75M in seed funding and gains Swisscom Ventures & Zürcher Kantonalbank as investors
Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 2.75M in seed funding and gained Swisscom Ventures as a strategic investor. Zürcher Kantonalbank also joined the financing round, alongside the existing shareholders, thus reaffirming their trust in the competence and vision of Scailyte’s team. Dominique Megret, Head […]
Press release: Resistell AG closes seed round Resistell AG has today closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test. 700,000 people die each year due to drug resistant infections. Unless we can […]
The lack of private investment for start-ups and small companies in Europe encouraged the EU commission to announce that 410 MIO Euro will be made available to innovative start-ups. The process to receive those funds shall be simplified. The purpose is to retain companies to migrate to the US. HEMEX is offering partnerships and joint-ventures […]
Switzerland is the leading nation for innovation for several years in a row, according to the Geneva-based World Intellectual Property Organization (WIPO). The other countries in the top five for 2017 were Sweden, the Netherlands, the United States and Britain. (WIPO global innovation index). Switzerland has held the top spot since 2011. Events like the […]
Non-Dilutive Research Funding for Swiss Biotech companies The Swiss Biotech Association invited HEMEX to an information event on 12 March 2018 in Bern (Switzerland), regarding the possibilities Swiss biotech companies have for accessing different national and international non-dilutive funding instruments. Our customer solutions team attended the presentations and would be happy to show you the different […]